Dr. Patrick M. Boland, MD
Medical Oncology (Medical Oncology Physician)
195 Little Albany St Ste 2701
New Brunswick, NJ 08901
Who else practices at this address →
Middlesex County includes mental health (21% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 139
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: Jefferson Medical College of Thomas Jefferson University
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NJ license 25MA10675000 -
Hematology & Oncology Physician
NJ license 25MA10675000 · NY license 271752
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Robert Wood Johnson University Hospital New Brunswick, NJ
- Robert Wood Johnson University Hospital - Somerset Somerville, NJ
Medical groups
- Rutgers Health-Rwj Scleroderma Program (391 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 410
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 239 | 60 |
| Established patient office or other outpatient visit, 20-29 minutes | 50 | 35 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 20 | 19 |
| Established patient office or other outpatient visit, 10-19 minutes | 19 | 12 |
| Established patient office or other outpatient visit, 40-54 minutes | 18 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in New Brunswick, NJ | 25 |
| Levothyroxine Sodium Other prescribers in New Brunswick, NJ | 21 |
| Oxycodone Hcl Other prescribers in New Brunswick, NJ | 19 |
| Imatinib Mesylate | 18 |
| Prochlorperazine Maleate Other prescribers in New Brunswick, NJ | 18 |
| Pantoprazole Sodium Other prescribers in New Brunswick, NJ | 17 |
| Trazodone Hcl Other prescribers in New Brunswick, NJ | 14 |
| Amlodipine Besylate Other prescribers in New Brunswick, NJ | 13 |
| Xarelto (rivaroxaban) Other prescribers in New Brunswick, NJ | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 16 payments worth $9,547 in total to this clinician.
| Syndax Pharmaceuticals, Inc. | $4,735 |
|---|---|
| Incyte Corporation | $4,682 |
| Genentech USA, Inc. | $68.00 |
| AstraZeneca Pharmaceuticals LP | $62.15 |
| Consulting Fee | $7,585 |
|---|---|
| Travel and Lodging | $1,445 |
| Food and Beverage | $517 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation May 15, 2025 | Consulting Fee ZYNYZ · Oncology | $4,110 |
| Syndax Pharmaceuticals, Inc. Sep 13, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $3,475 |
| Syndax Pharmaceuticals, Inc. Sep 13, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to NEW YORK, NY · in-kind | $487 |
| Incyte Corporation May 9, 2025 | Travel and Lodging ZYNYZ · Oncology · travel to Philadelphia, PA | $348 |
| Syndax Pharmaceuticals, Inc. Sep 13, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to NEW YORK, NY · in-kind | $312 |
| Syndax Pharmaceuticals, Inc. Sep 13, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to NEW YORK, NY · in-kind | $298 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $101,116 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.